DrugDashboards

Naropin

Ropivacaine Hydrochloride · ROPIVACAINE HYDROCHLORIDE 7.5 mg/mL · Injection, Solution · Epidural; Perineural · Fresenius Kabi USA, LLC

NDC 63323-0287-20 · 5 AMPULE in 1 BOX / 20 mL in 1 AMPULE · NDA · View full market →

The short version

15 companies supply this market — deep enough that no single failure threatens the supply. It is in shortage right now — FDA lists the reason as “other”. A Class II recall hit this product in the past year (Fresenius Kabi USA, LLC).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$0.0390per billing unit (1 MG)HCPCS J2795 · Jul 1, 2026
  • Federal ceiling (Big4)$45.77per package of 5X20MLFresenius Kabi, LLC · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$94.50
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$0.039
HCPCS J2795 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2022)

$238
41 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA020533
TE code
AP
Approval date
Sep 24, 1996
Patents / exclusivity
2 patents, 0 exclusivities
TypeNumber / codeExpires
patent7857802Nov 28, 2026
patent7857802Nov 28, 2026

Shortage history

  • In shortage now — Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)Mar 27, 2018
    Other
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)Mar 27, 2018
    Other
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)Mar 27, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)Mar 27, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)Mar 27, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)Mar 27, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)Mar 23, 2018
    Delay in shipping of the drug
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)Mar 23, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)Mar 23, 2018
    Delay in shipping of the drug
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)Mar 23, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)Mar 23, 2018
    Demand increase for the drug
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)Mar 23, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)Mar 23, 2018
    Other
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)Mar 23, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)Mar 23, 2018
    Other
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)Mar 23, 2018
    Other
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)Mar 23, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)Mar 23, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)Mar 23, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)Mar 23, 2018
    month 102 — 5× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months

Recalls (this NDC)

  • Class II · OngoingJul 16, 2026
    Fresenius Kabi USA, LLC — Presence of Particulate Matter: Hair was found in products

Manufacturers of Ropivacaine Hydrochloride (Injection, Solution)

LabelerStrengthFirst seenLast seen
Baxter Healthcare CorporationROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCROPIVACAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCROPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCROPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCROPIVACAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Gland Pharma LimitedROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Glenmark Pharmaceuticals Inc., USAROPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.ROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.ROPIVACAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.ROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.ROPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
SOLA Pharmaceuticals, LLCROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Anthea Pharma Private LimitedROPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Anthea Pharma Private LimitedROPIVACAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Anthea Pharma Private LimitedROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Eugia US LLCROPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCROPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Fresenius Kabi Usa, LlcROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Glenmark Pharmaceuticals Inc., USAROPIVACAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.ROPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.ROPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Meitheal Pharmaceuticals Inc.ROPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsROPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Sportpharm LLCROPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Mylan Institutional LLCROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 31, 2026
Sagent PharmaceuticalsROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 31, 2026
Excella GmbH & Co. KGROPIVACAINE HYDROCHLORIDE 1 kg/kgJul 15, 2026Aug 28, 2026
Fresenius Kabi USA, LLCROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 28, 2026
Glenmark Pharmaceuticals Inc., USAROPIVACAINE HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Naropin — NDC 63323-0287-20," retrieved September 3, 2026, https://drugdashboards.com/drug/63323028720.

Free to cite with attribution — see how the data is put together.